Blogir-3 tab. d / rassas. 5mg (blisters) # 30

Blogir-3 is a long-acting non-sedative antihistamine.

It is the primary active metabolite of loratadine.

Selectively blocks the activity of peripheral histamine H receptors.

Suppresses the release of histamine from mast cells.

Inhibits a cascade of reactions of allergic inflammation, including the release of anti-inflammatory cytokines, including interleukins IL-4, IL-6, IL-8, IL-13, the release of adhesion molecules such as P-selectin.

Thus, it prevents the development and facilitates the course of allergic reactions, has an antipruritic and antiexudative effect, reduces capillary permeability, prevents the development of tissue edema, spasm of smooth muscles.

The drug has no effect on the central nervous system, has practically no sedative effect (does not cause drowsiness) and does not affect the speed of psychomotor reactions.

Does not cause prolongation of the QT interval on the ECG.

Pharmacokinetics

After oral administration, desloratadine is well absorbed in the gastrointestinal tract, determined in the blood plasma 30 minutes after ingestion.

The maximum concentration Cmax is reached after about 3 hours.

Plasma protein binding of desloratadine is 83-87%.

When used in adults and adolescents for 14 days at a dose of 5 mg to 20 mg once a day, there were no signs of clinically significant cumulation of desloratadine.

The simultaneous intake of food or grapefruit juice does not affect the distribution of desloratadine (when taken at a dose of 7.5 mg 1 time per day).

Does not penetrate the blood-brain barrier.

It undergoes intensive metabolism in the liver by hydroxylation to form 3-OH-desloratadine, combined with glucuronide.

It is not an inhibitor of CYP3A4 and CYP2D6 isoenzymes and is not a substrate or inhibitor of P-glycoprotein.

Desloratadine is excreted from the body as a glucuronide compound and in small amounts (less than 2%) by the kidneys and through the intestines (less than 7%) unchanged.

Half-life T?

averages 27 hours.

Indications for use:

Indications for the use of Blogir-3 are: allergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus, itching in the nose, itching of the palate, itching and redness of the eyes, lacrimation)

urticaria (reduction or elimination of itching, rash).

Mode of application:

Inside, regardless of the meal.

It is necessary to carefully open the blister and take out the tablet without breaking it.

The Blogir-3 lozenge is put on the tongue, where it dissolves, after which it is swallowed with saliva without drinking water or other liquid.

The tablet should be taken immediately after opening the blister.

Adults and adolescents from 12 years old: 1 lozenge (5 mg) once a day to reduce the symptoms of allergic rhinitis (including seasonal and perennial allergic rhinitis) and urticaria.

For seasonal (intermittent) allergic rhinitis (with symptoms lasting less than 4 days per week or less than 4 weeks per year), the course of the disease should be assessed.

If symptoms disappear, the drug should be discontinued, if symptoms reappear, the drug should be resumed.

For perennial (persistent) allergic rhinitis (with symptoms lasting more than 4 days a week or more than 4 weeks a year), the drug should be taken during the entire exposure period of the allergen.

Side effects:

The most common adverse effects (> 1/100 to < 1/10) are fatigue, dry mouth and headache.

Very rarely (< 1/10 000), the following undesirable effects were noted:

From the side of the central nervous system: hallucinations, dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions.

On the part of the cardiovascular system: tachycardia, palpitations.

From the digestive system: abdominal pain, nausea, vomiting, dyspepsia

Name ENG

BLOGIR-3

Clinical and pharmacological group

Blocker of histamine H1 receptors.

Antiallergic drug

ATX code

Desloratadine

Dosage

5mg

Structure

1 tablet for blogging Blogir-3 contains the active substance: desloratadine 5 mg.

Excipients: mannitol - 133.5 mg, microcrystalline cellulose - 15.0 mg, croscarmellose sodium - 6.0 mg, polacrilin potassium - 5.0 mg, aspartame - 3.0 mg, magnesium stearate - 1.7 mg, flavor tutti-frutti (flavoring agents, maltodextrin, propylene glycol E1520, modified starch E1450) - 0.75 mg, iron dye red oxide - 0.7 mg, citric acid monohydrate - qs

Indications

Allergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus, itching in the nose, itchy palate, itchy and red eyes, watery eyes)

urticaria (reduction or elimination of itching, rash).

Contraindications

Hypersensitivity to drug components

pregnancy and lactation

age - up to 12 years

phenylketonuria.In the presence of severe renal failure, the drug should be taken with caution.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

INN / Active ingredient

desloratadine

Specifications

Category

Allergy

Scope of the drug

Ear, Throat, Nose

Release form

Tablet

Manufacturer country

Greece

Package quantity, pcs

thirty

Scope of application

Allergology

Minimum age from

12 years

Vacation conditions

Without recipe

Brand name

Belupo

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

R06AX27 Desloratadine

Dosage form

Oral Dispersible Tablets

The target audience

Children

Expiration date in days

1095

Package weight, g

35

Mode of application

:

Inside, regardless of food intake. < br> Carefully open the blister and remove the tablet without breaking it. Blogir-3 lozenge is placed on the tongue, where it dissolves, after which it is swallowed with saliva, without drinking water or other liquid. The tablet should be taken immediately after opening the blister. < br> Adults and adolescents from 12 years: 1 lozenge (5 mg) 1 time per day to reduce symptoms of allergic rhinitis (including seasonal and perennial allergic rhinitis) and urticaria. < br> For seasonal (intermittent) allergic rhinitis (with symptoms lasting less than 4 days a week or less than 4 weeks a year), the course of the disease should be assessed. When symptoms disappear, the drug should be discontinued,if symptoms reappear, the drug must be resumed. < br> For perennial (persistent) allergic rhinitis (with symptoms lasting more than 4 days a week or more than 4 weeks a year), the drug should be taken during the entire period of exposure to the allergen.

Pharmaco-therapeutic group

:

Antiallergic agent - H1-histamine receptor blocker

Dosage (volume) of the substance in the preparation

:

1 tablet for blogging Blogir-3 contains the active substance: desloratadine 5 mg.

Information on technical characteristics, delivery set, country of manufacture